Qcil POSTS RECORD PROFITS AND ANNOUNCES AMBITIOUS EXPANSION

 Kampala, Uganda – July 17, 2025 – Quality Chemical Industries Limited (Qcil), Uganda's leading pharmaceutical manufacturer, today presented its financial results for the year ended March 31, 2025, and unveiled its expansion plans at its Annual General Meeting (AGM). The Company’s ambitious plans underscore its ongoing commitment to public health and economic development in Uganda and the region. 

Strong Financial Performance 

Qcil presented its audited financial results, highlighting stable revenue of UShs 267.1 billion and an 18% increase in gross profit to a record UShs 108.5 billion. Net profit surged by 22% to a record UShs 40.7 billion, reflecting improved operational efficiency and disciplined financial management. 

In recognition of this outstanding performance, the Board recommended and shareholders approved a total dividend of UShs 13.5 per share for FY2024/25, more than double last year›s total payout of UShs 5.7 per share, reaffirming Qcil›s commitment to delivering value to its shareholders. 

'' This strong performance reflects our operational focus and public health mission,'' said 

Mr. Ajay Kumar Pal, CEO of Qcil. Our success is a testament to our team’s dedication. We thank our shareholders, team, and partners for their continued trust as we build for the future.'' 

_{Mr. Emmanuel Katongole (Chairman) and Mr. Ajay Kumar Pal (CEO) at the AGM}

A Pillar of Public Health: Combatting HIV and Malaria at Scale 

Qcil remains a critical player in Uganda’s response to major public health challenges, including HIV and malaria. Qcil manufactures 1.4 billion tablets annually at its Luzira factory, primarily WHO-prequalified antiretrovirals (ARVs) and antimalarials, ensuring reliable and affordable access to lifesaving medicines for millions.

''Qcil’s impact goes beyond numbers; we are saving lives by ensuring consistent access to essential medicines,'' stated Mr. Emmanuel Katongole, Chairman and Co-founder of Qcil. '' Our partnerships with the government and international health organizations ensure these critical treatments reach those who need them most.''

_{Grace Karuhanga (Company Secretary), Mr. Emmanuel Katongole, (Chairman) and Mr. Ajay Kumar Pal (CEO) at the AGM}

 Investing in the Future: Expanding Capacity to Meet Africa’s Evolving Health Needs 

Shareholders were also briefed on Qcil’s next phase of growth. The Company has secured a USD 36 million loan facility to construct a second manufacturing plant, a strategic investment that will expand Qcil’s annual capacity to 2.4 billion tablets and introduce new lines for tuberculosis treatments, injectables, and other innovative products. 

Qcil's economic contributions and social impact continue to grow, with tax payments consistently rising, reaching UShs 19.8 billion in 2025 (UShs 15.1 billion in 2024). Qcil also remains a major employer, an investor in local talent, and an active participant in community health initiatives. 

”We are investing in Uganda’s health and prosperity,” said Mr. Katongole. “This expansion will enable us to do more for our patients, our people, and our economy.”